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Abstract
OBJECTIVES—To compare the risk of pneumonia among older patients receiving donepezil, 
galantamine, or rivastigmine for dementia.
DESIGN, SETTING, AND PARTICIPANTS—Retrospective cohort study of a nationally 
representative 5% sample of Medicare beneficiaries 65 years or older who newly initiated 
cholinesterase inhibitor therapy between 2006 and 2009.
MEASUREMENTS—Pneumonia, defined as the presence of a diagnosis code for pneumonia as 
the primary diagnosis on an inpatient claim or on an emergency department claim followed by 
dispensing of appropriate antibiotics. We used Cox proportional hazards models to estimate the 
risk of pneumonia. We conducted secondary analyses and sensitivity analyses using alternative 
pneumonia definitions and adjustments by high-dimensional propensity scores to test the 
robustness of the results.
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RESULTS—Among 35,570 new users of cholinesterase inhibitors (30,174 users of donepezil, 
1176 users of galantamine, and 4220 users of rivastigmine), mean age was 82 years, 75% were 
women, and 82% were white. The cumulative incidence of pneumonia was 51.9 per 1000 person-
years. Risk was significantly lower by 24% among rivastigmine users compared with donepezil 
users (hazard ratio [HR], 0.75; 95% CI, 0.60–0.93). Risk among galantamine users (HR, 0.87; 
95% CI, 0.62–1.23) was not significantly different from risk among donepezil users. Results of 
secondary and sensitivity analyses were similar to the primary results.
CONCLUSION—The risk of pneumonia was lower among patients receiving rivastigmine 
compared with patients receiving donepezil. Additional studies are needed to confirm the findings 
of pneumonia risk between the oral and transdermal forms of rivastigmine and among users of 
galantamine.
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INTRODUCTION
Dementia is a chronic neurodegenerative disorder characterized clinically by deterioration of 
daily living, behavioral functioning, and global cognitive ability.1,2 Cholinesterase inhibitors 
are the cornerstone of medical therapy and are approved for symptomatic treatment of 
patients with mild to moderate dementia.2 Because pneumonia is a common cause of death 
in older patients with dementia,3,4 the potential risk of pneumonia associated with 
cholinesterase inhibitors has raised concern.2,5 Cholinesterase inhibition may lead to over 
activation of muscarinic receptors and result in bradycardia, bronchospasm, emesis, and 
diarrhea. Moreover, overstimulation of nicotinic receptors results in fasciculation, muscle 
weakness, and paralysis that may increase pneumonia risk.5,6 Although there is no direct 
evidence of greater pneumonia risk associated with cholinesterase inhibitors, results of 
randomized clinical trials have suggested the possibility.7,8 Helou et al5 found that 
cholinesterase inhibitor therapy in 183 hospitalized patients with dementia was associated 
with nearly double the risk of pulmonary disorders, mostly pneumonia.5
We evaluated the comparative risk of pneumonia among older patients receiving donepezil, 
galantamine, or rivastigmine. Rivastigmine inhibits both acetylcholinesterase and 
butyrylcholinesterase and has greater selectivity for brain tissue than peripheral tissues.2,9 
Some studies have indicated that rivastigmine has lower affinity for the type 4 globular 
isoform of acetylcholinesterase than the type 1 isoform, a possible safety improvement 
because the type 4 isoform predominates in the peripheral nervous system.10,11 Because the 
peripheral nervous system regulates involuntary physiological functions such as breathing 
and digestion, cholinesterase inhibitors with fewer peripheral effects are less likely to cause 
unintended respiratory outcomes, such as shortness of breath and dyspnea, or unintended 
digestive outcomes, such as gastro-esophageal reflux or esophageal immotility, which may 
have a negative impact on pneumonia risk.5,6,12 However, no evidence exists for the 
comparative safety of cholinesterase inhibitors with regard to pneumonia risk. We 
hypothesized that rivastigmine posed a lower risk than donepezil and galantamine, which are 
acetylcholinesterase inhibitors without selectivity for the type 4 isoform.10,11
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We accessed administrative claims data from January 1, 2006, through December 31, 2009, 
for a nationally representative 5% sample of Medicare beneficiaries. The institutional review 
board of the Duke University Health System approved the study. The data included 
inpatient, outpatient, carrier, and prescription drug event claims and corresponding 
denominator files. Diagnostic and procedural information from the inpatient, outpatient, and 
carrier files included International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes and Current Procedural Terminology (CPT) codes. We 
obtained drug information from Medicare Part D claims. Medicare Part D subsidizes the 
costs of prescription drugs for Medicare beneficiaries. Beneficiaries with Medicare Parts A 
and B are eligible for Part D. The claims are registered by the date of dispensing, days of 
supply, dose dispensed, and a National Drug Code for each formulation.
Cohort Definition and Exposure
We identified patients 65 years or older who were newly prescribed a cholinesterase 
inhibitor. We considered the first dispensed cholinesterase inhibitor to be the index 
medication, and we used the dispensing date as the index date. We included new users who 
did not receive medication for dementia during the 6 months before the index date. To 
ensure sufficient data to assess baseline characteristics, we excluded patients with less than 
12 months of continuous enrollment in Medicare Parts A and B and less than 6 months of 
continuous enrollment in Medicare Part D before the index date.
We classified eligible patients into 3 exposure groups by index medication: donepezil, 
galantamine, and rivastigmine. We defined 3 dosage levels (numbered 1, 2, and 3) based on 
the last prescription before the end of follow-up.
Outcomes and Follow-up
The outcome of interest was pneumonia, defined as the presence of ICD-9-CM codes 
480.xx–486.xx as the primary diagnosis on an inpatient claim or on an emergency 
department claim followed by dispensing of appropriate antibiotics (i.e., erythromycin, 
clarithromycin, ciprofloxacin, levofloxacin, moxifloxacin, doxycycline, amoxicillin, 
gemifloxacin, cefpodoxime, cefuroxime, azithromycin, doxycycline, and amoxicillin/
clavulanic acid). This identification of an inpatient pneumonia diagnosis has a positive 
predictive value of 88%.10 The follow-up period for each patient lasted until the patient 
received a pneumonia diagnosis, switched from the index medication, discontinued the 
medication (i.e., no dispensing for more than 30 days after the end date of the previous 
dispensing), discontinued enrollment in Medicare, or reached the end of the study(December 
31, 2009).
Covariates
We assessed demographic characteristics, health services utilization, history of pneumonia, 
and comorbid conditions during the 12 months before the index date. We also assessed the 
use of other medications during the 6 months before the index date. We identified history of 
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pneumonia by the presence of ICD-9-CM codes 480.xx–486.xx and 507.xx on inpatient and 
outpatient claims. We also assessed the use of antipsychotic medications and diagnoses of 
Lewy body disease (ICD-9-CM code 331.82) and Parkinson disease (ICD-9-CM code 
332.xx). Patients taking antipsychotics have a higher risk of pneumonia.13 Lewy body 
disease and Parkinson disease also are known to be associated with greater pneumonia 
risk.14
Statistical Analysis
We report the number of events and the incidence per person-year for the outcomes of 
interest. We plotted cumulative incidence, which represents the cumulative probability of 
events over time while accounting for competing risks.15 We then estimated hazard ratios 
(HRs) and 95% CIs using Cox proportional hazards models to assess pneumonia risks 
associated with galantamine and rivastigmine compared with donepezil. We adjusted for 
demographic characteristics and other covariates to account for potential confounding. We 
conducted subgroup analyses by stratifying patients by age, sex, race, and history of 
pneumonia, Parkinson disease (or receiving anti-Parkinson medication), Lewy body disease, 
and use of antipsychotics.
In secondary and sensitivity analyses, we tested the robustness of the results. We used high-
dimensional propensity score estimation to control for confounders and unobserved 
factors.16,17 Using a high-dimensional propensity score algorithm, we screened the data to 
identify covariates that may act collectively as surrogates for unobserved confounding 
factors.17 We included the propensity score as a continuous covariate in regression models 
or matched on the score using a greedy matching method, which reduces bias from 
incomplete and inexact matching.18
We repeated the analyses with various exposure and outcome definitions. Although 
aspiration pneumonia was coded infrequently, and the accuracy of the coding was unclear, 
we added aspiration pneumonia (ICD-9-CM code 507.xx) to the main outcome definition 
insensitivity analysis. We varied the grace period for defining discontinuation (0, 7, and 90 
days). We also varied the window for capturing antibiotic use for pneumonia identified in 
the emergency department. To evaluate the impact of censoring, we conducted an intention-
to-treat analysis in which we considered patients to be exposed to the index medication until 
the occurrence of pneumonia, death, or the end of follow-up, regardless of subsequent 
changes in exposure. We limited the follow-up period to 1 year. We used SAS version 9.3 
(SAS Institute, Inc) for all analyses.
RESULTS
Of 35,570 new users of cholinesterase inhibitors, 30,174 were users of donepezil, 1176 were 
users of galantamine, and 4220 were users of rivastigmine. Table 1 shows the baseline 
characteristics of the study population. Mean age was 81.6 (SD, 7.3) years, 26,542 
(74.6%)of the patients were women, and 29,265 (82.3%) were white. Some patients had a 
history of pneumonia (13.1%) and chronic obstructive pulmonary disease (28.2%). 
Galantamine users generally had lower rates of health service utilization. A greater 
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proportion of rivastigmine users had Parkinson disease (13.9%), Lewy body disease (7.0%), 
and use of antipsychotics (19.9%) and anti-Parkinson medication (11.8%).
There were 1249 cases of pneumonia during the mean follow-up period of 246.9 days. The 
cumulative incidence of pneumonia was 51.9 per 1000 person-years. Incidence was highest 
among donepezil users (52.6 per 1000 person-years), followed by galantamine users (42.9 
per 1000 person-years) and rivastigmine users (42.0 per 1000 person-years). The incidence 
curves in Figure 1 indicate that the rate of pneumonia was significantly lower among 
rivastigmine users than among donepezil users (P < .01). The unadjusted pneumonia risk 
was lower with rivastigmine (HR, 0.76; 95% CI, 0.62–0.95) and galantamine (HR, 0.76; 
95% CI, 0.52–1.10). After multivariable adjustment, pneumonia risk remained significantly 
lower with rivastigmine (HR, 0.75; 95% CI, 0.60–0.93), whereas the risk was not 
significantly different between galantamine and donepezil (HR, 0.87; 95% CI, 0.62–1.23). 
When we assessed pneumonia risk between the oral and transdermal forms of rivastigmine, 
we observed 39% and 14% lower risks, respectively, compared with donepezil (Table 2).
As shown in Table 2, pneumonia risk increased with advancing age and was greater among 
men, patients with a history of pneumonia, and patients with heart failure, chronic 
obstructive pulmonary disease, and previous use of antipsychotics, antidepressants, 
antiepileptic agents, and loop diuretics.
In secondary analyses and sensitivity analyses, the HRs were similar to those in the primary 
analysis (Figure 2). We found lower risks of pneumonia among rivastigmine users compared 
with donepezil users (HRs ranging from 0.38 to 0.95), and the risks were similar between 
galantamine users and donepezil users (HRs ranging from 0.75 to 1.10). Pneumonia risk was 
even lower among rivastigmine users compared with donepezil users among those who had 
Parkinson disease or Lewy body disease (HR, 0.43; 95% CI, 0.22–0.94), whereas it was not 
significant among those who did not have these conditions (HR, 0.84; 95% CI, 0.67–1.05).
DISCUSSION
In this large retrospective cohort study of a nationally representative sample of Medicare 
beneficiaries, the rivastigmine group had a higher proportion of patients with Parkinson 
disease, Lewy body disease, and use of antipsychotics and anti-Parkinson medication, 
suggesting that rivastigmine users may have a higher baseline risk of pneumonia. Despite the 
potential for residual confounding due to baseline risk that likely led us to underestimate 
potential beneficial effects of rivastigmine on pneumonia risk, new users of rivastigmine had 
significantly lower pneumonia risk compared with new users of donepezil after multivariable 
adjustment.
Previous research indicated that annual rates of hospital admission in the United States 
among older persons with pneumonia ranged from 15 to 25 per 1000.19 The rate of 
pneumonia in our study was approximately twice that observed in the previous report, 
suggesting that the study population had higher risk due to underlying disease, dementia, 
and/or use of cholinesterase inhibitors. Patients with dementia may have higher pneumonia 
risk because of limited activities of daily living,5,20 and difficulty swallowing may cause 
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aspiration pneumonia.21 This finding addresses questions about whether the increased risk 
of pneumonia among new users of rivastigmine is caused by dementia or by the 
medication.20 In addition to our hypothesis of fewer effects on muscarinic and nicotinic 
receptors, the lower risk of pneumonia with rivastigmine may be a result of greater 
effectiveness of the drug. However, evidence from clinical trials that directly compared the 
efficacy of cholinesterase inhibitors is conflicting.22–25 Therefore, it is less likely that 
physicians chose one cholinesterase inhibitor over another for patients with more or less 
severe dementia.
To our knowledge, our study is the first to assess the comparative risk of pneumonia among 
cholinesterase inhibitors. Despite the higher incidence of Parkinson disease and other 
comorbid conditions that might have resulted in worse outcomes among rivastigmine users, 
this group had lower risk of pneumonia compared with the donepezil group. Rivastigmine 
provides functional inhibition of both acetylcholinesterase and butyrylcholinesterase, 
whereas donepezil provides no functional inhibition of butyrylcholinesterase. 
Butyrylcholinesterase inhibition yields cognitive improvements inpatients with 
dementia.9,26–28 Furthermore, the preferential affinity of rivastigmine for the type 1 globular 
isoform of acetylcholinesterase over the type 4 isoform may contribute to improved safety, 
because the type 4 isoform predominates in the peripheral nervous system.29,30 As we 
hypothesized, the risk of pneumonia among rivastigmine users was lower than among 
donepezil users, which may be a result of reduced effects of rivastigmine on the peripheral 
nervous system. In addition, rivastigmine is not substantially metabolized by the hepatic 
microsomal cytochrome P450 system. It also has a low protein binding affinity, so it is less 
likely to compete with a high protein binding drug.9 Therefore, the increased risk of 
pneumonia may also result from unintended fluctuation in plasma concentration of 
donepezil due to drug-drug interaction.31 It is noteworthy that, compared with donepezil, the 
risk of pneumonia among rivastigmine users with Parkinson disease (or patients receiving 
anti-Parkinson medication) or Lewy body disease was lower than the risk among 
rivastigmine users without these conditions in sensitivity analysis. This finding may suggest 
greater effectiveness of rivastigmine in patients with dementia and Parkinson disease,32–34 
leading to a greater protective effect, especially for patients with those conditions.
Galantamine is a tertiary alkaloid compound with efficacy comparable to donepezil.23 
Because donepezil is an older drug, physicians are more familiar with it, which may help to 
explain its higher use. In addition, it was the first drug to have a generic equivalent. The 
relatively short half-life of galantamine requires twice-daily administration, which may 
partially explain the lower use of galantamine compared with the other medications. 
Galantamine users had a slightly lower risk of pneumonia compared with donepezil users, 
although this finding was not statistically significant, partly due to the smaller cohort size. 
Although Meguro et al12 found that donepezil had a positive effect on life expectancy, this 
finding may be related to the lower mortality rate from pneumonia or respiratory failure 
compared with the galantamine or memantine group. We were unable to differentiate the 
effects of galantamine from memantine. In summary, the comparative risk of pneumonia 
between galantamine and donepezil remains inconclusive based on current evidence.
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After stratifying by the oral and transdermal patch formulations of rivastigmine, we found a 
smaller, non significant reduction in pneumonia among users of the patch. With its 
introduction to the United States in 2007, the patch offered a more favorable gastrointestinal 
tolerability profile and steadier drug plasma concentration than oral rivastigmine.35 
Treatment adherence may be improved by transdermal delivery, imparting clinical benefits 
and fewer side effects such as pneumonia. Patch users may have more advanced dementia 
than oral rivastigmine users, so possible confounding by indication should be noted. 
Although we performed a series of adjustments to minimize bias, future studies with more 
precise assessments of pneumonia risk between the oral and patch formulations are 
warranted.
Our findings are consistent with previous reports of risk factors associated with pneumonia 
risk.36–38 The association between antipsychotics and pneumonia risk maybe explained by 
the mechanism of action on neurotransmitters.39,40 Also, antipsychotic use may be a 
surrogate for more severe dementia; we were unable to directly measure and account for 
dementia severity in our data set.11 We also found that the use of antiepileptic medication 
increased the risk of pneumonia. Although there is no direct evidence for this association, 
Yang et al41 noted that concomitant use of antiepileptic medication with antipsychotics 
would significantly increase pneumonia risk compared with use of antipsychotics alone.41 
One study found that pneumonia was 3 times as likely afterhospitalization for depression, 
implying that antidepressants may also increase pneumonia risk.42 We found that the use of 
antidepressants was associated with pneumonia risk, but the risk was much lower after 
multivariable adjustment.43
Pneumonia is one of the most life-threatening complications of Parkinson disease and Lewy 
body disease.14,44 We observed small but non significant increases in pneumonia risk. This 
finding can be explained by our combined definition of “Parkinson disease or Lewy body 
disease,” resulting in low statistical power and misclassification bias toward the null. On the 
other hand, use of angiotensin-converting enzyme (ACE) inhibitors was associated with 
lower pneumonia risk. ACE inhibitors are known to enhance the cough reflex and protect the 
tracheobronchial tree by avoiding exposure of the respiratory tree to oropharynx secretions, 
which may reduce the incidence of pneumonia.45
Our study has limitations. First, Medicare data do not include information on dementia 
severity. Donepezil may be used for moderate to severe dementia; thus, residual confounding 
by severity is possible. However, we believe the confounding effect was relatively small 
when compared among users of cholinesterase inhibitors, because prescribers may pay more 
attention to patients’ situations when choosing a cholinesterase inhibitor rather than pay 
attention to labeled indication relative to severity. Second, the dose of last prescription may 
reflect the most recent status of drug level before the pneumonia event. Although we did not 
observe a dose-response relationship, inclusion of last dose in the regression models may 
partially adjust for the most recent status of the patient, such as health, disease, or drug 
tolerability status. Third, the diagnosis reported in emergency department claims has not 
been validated. Although we used the dispensing of appropriate antibiotics to increase the 
validity of the diagnosis, we could not eliminate the possibility of misclassification. Fourth, 
we included only new users in an attempt to create a relatively homogenous cohort. Also, the 
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data indicate that the rivastigmine group had conditions associated with higher risk of 
pneumonia, in that the group had a higher proportion of patients with Parkinson disease, 
Lewy body disease, and the use of antipsychotics and anti-Parkinson medication. 
Nonetheless, we used multivariable adjustment and high-dimensional propensity score 
estimation to control for factors that may have been surrogates for disease severity. Fifth, the 
mortality rate was high, which may have introduced competing risks for pneumonia 
outcomes. We used the cumulative incidence function to address competing risks, and the 
results remained robust. Finally, we only assessed comparative safety among users of 
cholinesterase inhibitors, and we did not include a non treatment group because such 
patients were uncommon and may not be comparable to those receiving cholinesterase 
inhibitors due to different baseline risk of pneumonia. No inference can be made about risks 
associated with cholinesterase inhibitors compared with no treatment.
CONCLUSION
Rivastigmine posed a lower risk of pneumonia compared with donepezil in patients with 
dementia who newly initiated cholinesterase inhibitor therapy. Additional studies are needed 
to confirm the findings, including more precise assessments of pneumonia risk between the 
oral and transdermal forms of rivastigmine and among users of galantamine.
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Cumulative Incidence of Pneumonia Risk Among New Users of Cholinesterase Inhibitors
Note: P < .01 for comparisons between the index medications.
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Secondary and Sensitivity Analyses of Pneumonia Risk Among New Users of 
Cholinesterase Inhibitors
Note: High-dimensional propensity scores were generated by donepezil-galantamine group 
and donepezil-rivastigmine group, respectively.
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Table 2
Cox Proportional Hazards Regression Model for Risk of Pneumonia Among New Users of Cholinesterase 
Inhibitors
Parameter Unadjusted HR (95%CI) Adjusted HR (95%CI)
Index medication
 Donepezil 1.00 [Reference] 1.00 [Reference]
 Galantamine 0.76(0.52–1.10) 0.87(0.62–1.23)
 Rivastigminea 0.76(0.62–0.95) 0.75(0.60–0.93)
  Oral rivastigmine 0.70(0.48–1.03) 0.61(0.41–0.89)
  Transdermal rivastigmine 0.85(0.65–1.11) 0.85(0.66–1.10)
Age (per 1 year) 1.03(1.02–1.03) 1.03(1.02–1.03)
White race 1.02(0.89–1.17) 1.04(0.91–1.20)
Male sex 1.39(1.24–1.56) 1.59(1.43–1.78)
Last prescription before end of follow-upb
 Dosage level 1 1.00 [Reference] 1.00 [Reference]
 Dosage level 2 0.38(0.09–1.52) 0.94(0.85–1.04)
 Dosage level 3 0.89(0.80–0.99) 0.44(0.11–1.79)
Parkinson disease or Lewy body disease 1.16(0.97–1.40) 1.15(0.92–1.44)
History of pneumonia 3.21(2.87–3.60) 1.66(1.46–1.88)
Health service use
 Hospital admission 1.34(1.30–1.38) 1.13(1.08–1.18)
 Outpatient clinic visit 1.00(1.00–1.01) 1.00(0.99–1.00)
 Emergency department visit 1.02(1.02–1.02) 1.00(1.00–1.01)
 Skilled nursing facility admission 1.85(1.67–2.06) 0.93(0.82–1.05)
 Prescription 1.01(1.01–1.01) 1.00(1.00–1.01)
Comorbid conditions
 Arrhythmia 1.54(1.38–1.71) 0.99(0.89–1.11)
 Cancer 1.02(0.87–1.20) 0.87(0.75–1.01)
 Cerebrovascular disease 1.21(1.09–1.34) 0.92(0.82–1.02)
 Chronic obstructive pulmonary disease 2.53(2.28–2.81) 1.72(1.54–1.91)
 Depression 1.21(1.08–1.36) 0.89(0.78–1.01)
 Diabetes mellitus 1.21(1.09–1.34) 0.94(0.81–1.09)
 Dyslipidemia 0.76(0.68–0.84) 0.79(0.71–0.88)
 Heart failure 2.16(1.95–2.41) 1.20(1.07–1.35)
 Hypertension 1.37(1.17–1.60) 0.97(0.83–1.14)
 Liver disease 1.32(1.05–1.66) 1.07(0.86–1.33)
 Mood disorder 1.21(1.05–1.41) 0.88(0.75–1.02)
 Myocardial infarction or ACS 1.54(1.33–1.79) 0.95(0.81–1.10)
 Renal disease 1.67(1.47–1.89) 0.97(0.85–1.11)
 Schizophrenia 1.16(0.84–1.61) 0.91(0.66–1.26)
Medications
 ACE inhibitor 1.00(0.89–1.12) 0.90(0.80–1.00)
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Parameter Unadjusted HR (95%CI) Adjusted HR (95%CI)
 Antidepressive agent 1.43(1.28–1.58) 1.19(1.06–1.33)
 Antidiabetic agent 1.23(1.09–1.38) 1.14(0.97–1.35)
 Antiepileptic agent 1.52(1.32–1.75) 1.15(1.00–1.32)
 Antihyperlipidemic non-statin 0.84(0.67–1.05) 0.85(0.68–1.07)
 Antihyperlipidemic statin 0.85(0.77–0.95) 0.98(0.86–1.11)
 Anti-infective agent 1.63(1.47–1.81) 1.21(1.08–1.34)
 Anti-Parkinson agent 1.05(0.84–1.31) 0.83(0.63–1.10)
 Antipsychotic agent 1.49(1.32–1.68) 1.13(1.00–1.28)
 β-Blocker 1.06(0.95–1.17) 0.87(0.78–0.97)
 Calcium channel blocker 1.21(1.09–1.36) 1.06(0.95–1.19)
 Loop diuretic 1.78(1.60–1.98) 1.14(1.01–1.29)
 Thiazide diuretic 0.97(0.82–1.15) 1.07(0.91–1.25)
Abbreviations: ACS, acute coronary syndrome; ACE, angiotensin-converting-enzyme; HR, hazard ratio.
a
We separated the use of rivastigmine by formulations and repeated the analysis.
b
We defined dosage level 1 as donepezil 5 mg, galantamine 4 mg, oral rivastigmine 3 mg, and transdermal rivastigmine 4.6 mg; dosage level 2 as 
donepezil 10 mg, galantamine 24 mg, oral rivastigmine 12 mg, and transdermal rivastigmine 9.5 mg; and dosage level 3 as donepezil > 10 mg, 
galantamine > 24 mg, oral rivastigmine > 12 mg, and transdermal rivastigmine > 9.5 mg.
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